Status | Study |
Completed |
Study Name: A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) Condition: Lambert Eaton Myasthenic Syndrome Date: 2011-06-17 Interventions: Drug: Amifampridine Phosphate |
No longer available |
Study Name: Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome Condition: Lambert-Eaton Myasthenic Syndrome Date: 2011-06-13 Interventions: Drug: 3,4 DAP Recommended maximum dosage: 20mg four times daily and if needed an additional 20 mg per da |
Completed |
Study Name: MC-5A for Chemotherapy Induced Peripheral Neuropathy Condition: Neuropathy, Paraneoplastic Date: 2010-12-09 Interventions: Device: MC-5A 45 minutes daily |
Completed |
Study Name: Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes Condition: Congenital Myasthenic Syndrome Date: 2010-09-15 Interventions: Drug: Albuterol 4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or |
Available |
Study Name: Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine Condition: Lambert-Eaton Myasthenic Syndrome Date: 2009-10-08 Interventions: Drug: 3,4 diaminopyridine 3,4 diaminopyridine up to 80 mg daily in divided doses |
Completed |
Study Name: Studies of Neurological Paraneoplastic Syndromes Condition: Paraneoplastic Neurologic Degenerations (PNDs) Date: 2007-12-21 |
Completed |
Study Name: One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study Condition: Osteoporosis Humoral Hypercalcemia of Malignancy Hyperpara Date: 2007-12-20 Interventions: Drug: PTHrP (1-36) IND # 49,175 Other Name: Parathyr |
Active, not recruiting |
Study Name: Ephedrine for the Treatment of Congenital Myasthenia Condition: Myasthenic Syndromes, Congenital Date: 2007-10-07 Interventions: Drug: Ephedrine |
Completed |
Study Name: Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone Condition: Breast Cancer Hypercalcemia of Malignancy Metastatic Cance Date: 2007-04-09 Interventions: Drug: zoledronic acid Procedure: quality-o |
Completed |
Study Name: Immunotherapy of the Paraneoplastic Syndromes Condition: Paraneoplastic Syndromes Date: 2006-09-18 Interventions: Drug: Tacrolimus Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction wit |